Science News
from research organizations

Alzheimer's drug prescribed off-label could pose risk for some

Date:
February 25, 2017
Source:
University of California - Los Angeles Health Sciences
Summary:
Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. Researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline.
Share:
FULL STORY

Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment without a genetic test. UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation -- the K-variant of butyrylcholinesterase, or BChE-K -- donezpezil could accelerate cognitive decline.

Mild cognitive impairment is a transitional state between normal age-related changes in cognition and dementia. Because many people with the condition display symptoms similar to those caused by Alzheimer's disease, some physicians prescribe donepezil, which is marketed under the brand name

Aricept and is the most-prescribed medication for Alzheimer's.

Donepezil was tested as a possible treatment for mild cognitive impairment in a large, federally funded study published in 2005, but it was not approved by the FDA. Still, doctors have often prescribed the drug "off-label" -- meaning that it is not approved for that specific disorder -- for their patients with mild cognitive impairment.

From data collected during the 2005 trial, the researchers looked at the association between BChE-K and changes in cognitive function. Using two tests that measure cognitive impairment, the Mini-Mental State Examination and the Clinical Dementia Rating Sum of Boxes, they found that people with the genetic variation who were treated with donepezil had greater changes in their scores than those who took placebos. They also found that those who took donepezil had a faster cognitive decline than those who took the placebo.

Physicians are increasingly using personalized medicine, including pharmacogenetics -- the study of how genetics affect a person's response to a drug -- to tailor their patients' care. The findings reinforce the importance of physicians discussing the possible benefits and risks of this treatment with their patients.

The study was published in the Journal of Alzheimer's Disease.


Story Source:

Materials provided by University of California - Los Angeles Health Sciences. Original written by Laura Perry. Note: Content may be edited for style and length.


Journal Reference:

  1. Louis De Beaumont, Sandra Pelleieux, Louise Lamarre-Théroux, Doris Dea, Judes Poirier. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. Journal of Alzheimer's Disease, 2016; 54 (3): 913 DOI: 10.3233/JAD-160373

Cite This Page:

University of California - Los Angeles Health Sciences. "Alzheimer's drug prescribed off-label could pose risk for some." ScienceDaily. ScienceDaily, 25 February 2017. <www.sciencedaily.com/releases/2017/02/170225102126.htm>.
University of California - Los Angeles Health Sciences. (2017, February 25). Alzheimer's drug prescribed off-label could pose risk for some. ScienceDaily. Retrieved May 24, 2017 from www.sciencedaily.com/releases/2017/02/170225102126.htm
University of California - Los Angeles Health Sciences. "Alzheimer's drug prescribed off-label could pose risk for some." ScienceDaily. www.sciencedaily.com/releases/2017/02/170225102126.htm (accessed May 24, 2017).

RELATED STORIES